NMPA Accepts Bio-Thera Solutions’ Biologics License Application (BLA) for BAT1706, A Proposed Biosimilar to Avastin®

Bio-Thera Solutions announced that the China National Medical Products Administration (NMPA) has accepted the Biologics License Application for BAT1706, a proposed biosimilar to Avastin®.
[Bio-Thera Solutions (Business Wire, Inc.)]
Press Release
Bookmark

No account yet? Register

0
Share

3D Printed Deformable Sensors

The authors developed an in situ 3D printing system that estimated the motion and deformation of the target surface to adapt the toolpath in real time. With this printing system, a hydrogel-based sensor was printed on a porcine lung under respiration-induced deformation.
[Science Advances]
Full Article
Bookmark

No account yet? Register

0
Share

Adamis Pharmaceuticals Announces License to Commercialize Tempol, a Novel Investigational Anti-inflammatory and Antioxidant Drug for the Treatment of Respiratory Diseases Including COVID-19

Adamis Pharmaceuticals Corporation announced a license to commercialize Tempol, a novel patented investigational drug for the treatment of COVID-19. The license includes the worldwide use of Tempol for the treatment of all respiratory diseases including asthma, respiratory syncytial virus, influenza and COVID-19.
[Adamis Pharmaceuticals]
Press Release
Bookmark

No account yet? Register

0
Share

Differential Functions of ERK1 and ERK2 in Lung Metastasis Processes in Triple-Negative Breast Cancer

Investigators provided evidence supporting the notion that ERK1 and ERK2 have functionally distinct properties and that ERK2, not ERK1, primarily contributed to lung metastasis in a riple negative breast cancer mouse model.
[Scientific Reports]
Abstract
Bookmark

No account yet? Register

0
Share
Share